ClinicalTrials.gg
Sign In

Hangzhou DAC Biotechnology Co., Ltd. clinical trials

The registry lists 7 studies whose lead sponsor is Hangzhou DAC Biotechnology Co., Ltd.. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 12, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Get an email when these change. Save the Hangzhou DAC Biotechnology Co., Ltd. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Pipeline: 5 programmes

Each counted once: 5 with a study Hangzhou DAC Biotechnology Co., Ltd. leads registered in the last two years.

  • Phase 1

The 5 programmes — sign in to see the list, free: with every programme, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Hangzhou DAC Biotechnology Co., Ltd.’s own registered studies; Hangzhou DAC Biotechnology Co., Ltd.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

Coming up

1 of Hangzhou DAC Biotechnology Co., Ltd.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. M
  6. A
  7. M
  8. 1J
  9. J
  10. A
  11. S
  12. O
  13. N

The study

Add it to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 15, 2026.

Newly registered1

All 7 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now7100%Recruiting 5 · Not yet recruiting 2

Phase

  • Phase 17
  • Phase 21

Where

  • China7

Over the years

  1. 24
  2. 25
  3. 526

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Hangzhou DAC Biotechnology Co., Ltd..

  • Hangzhou DAC Biotechnology Co., Ltd.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    7 studies

Studies

Recruiting first, then most recently updated. Showing 7 of 7.